QGENQiagen N.V.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 81). Price is +18% vs its 200-day average.
Moderately shorted, settled Sep 30, 2026, about a week of normal trading to cover. Level with the previous count, up from 3.0% of shares outstanding three months ago.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How QGEN is trading
Qiagen N.V. is +4.7% over the past year while the S&P 500 is +16%: 11 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +18%
vs 200-day average · a clear uptrend
- RSI (14)
- 81
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 9.5%
Below its 52-week high
Details›
- Last close2026-10-23
- $50.39
- 1 monthS&P 500 −0.94%
- +13%
- 1 yearS&P 500 +16%
- +4.7%
- 5 yearsS&P 500 +86%
- −0.35%
- vs 50-day average$44.42
- +13%
- 52-week high
- $55.66
- 52-week low
- $32.63
- Annualised volatility
- 31%
| Year | Return |
|---|---|
| 2026 (year to date) | +12% |
| 2025 | +1.5% |
| 2024 | +2.4% |
| 2023 | −13% |
| 2022 | −10% |
| 2021 | +5.2% |
| 2020 | +56% |
| 2019 | −1.9% |
| 2018 | +11% |
| 2017 | +11% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +2.9% |
| Feb | 10 | 4 of 10 | −2.8% |
| Mar | 10 | 5 of 10 | +0.08% |
| Apr | 10 | 4 of 10 | −1.9% |
| May | 10 | 9 of 10 | +4.4% |
| Jun | 10 | 4 of 10 | +1.3% |
| Jul | 11 | 8 of 11 | +6.1% |
| Aug | 11 | 5 of 11 | −0.57% |
| Sep | 11 | 3 of 11 | −3.1% |
| Oct | 11 | 5 of 11 | −0.77% |
| Nov | 10 | 7 of 10 | +7.7% |
| Dec | 10 | 6 of 10 | −1.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Diagnostics & Research
Ranks #2 of 21 by RyuScore